Virtus ETF Advisers LLC Trims Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Virtus ETF Advisers LLC decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 13.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,007 shares of the biotechnology company’s stock after selling 6,858 shares during the quarter. Virtus ETF Advisers LLC’s holdings in BioCryst Pharmaceuticals were worth $346,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Xponance Inc. lifted its position in shares of BioCryst Pharmaceuticals by 9.1% in the 4th quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 1,242 shares during the period. Sei Investments Co. raised its stake in BioCryst Pharmaceuticals by 2.8% in the fourth quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company’s stock worth $430,000 after buying an additional 1,537 shares in the last quarter. SkyView Investment Advisors LLC lifted its holdings in BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after buying an additional 3,000 shares during the period. Mariner LLC boosted its position in BioCryst Pharmaceuticals by 32.1% during the 4th quarter. Mariner LLC now owns 13,258 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 3,224 shares in the last quarter. Finally, Arizona State Retirement System boosted its position in BioCryst Pharmaceuticals by 6.6% during the 4th quarter. Arizona State Retirement System now owns 57,001 shares of the biotechnology company’s stock valued at $429,000 after acquiring an additional 3,518 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on BCRX. JMP Securities restated a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Needham & Company LLC reissued a “buy” rating and set a $15.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 10th. Evercore ISI upped their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Wedbush began coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock opened at $8.39 on Friday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.11 and a 1 year high of $9.50. The firm’s 50-day moving average is $7.72 and its 200 day moving average is $7.76. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -13.75 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. The business’s quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.28 EPS. On average, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.